PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Theravectys

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

THERAVECTYS Launches its New Website & Wins Deloitte Technology Fast50 2014 Biotech D’Avenir Award - THERAVECTYS wins Deloitte Technology Fast50 2014 Biotech d’Avenir, a prize awarded to one of the fastest-growing, most innovative & dynamic biotech company of the year - Theravectys.com
THERAVECTYS Launches its New Website & Wins Deloitte Technology Fast50 2014 Biotech D’Avenir Award

 

NewswireToday - /newswire/ - Villejuif, Ile-de-France, France, 2014/12/16 - THERAVECTYS wins Deloitte Technology Fast50 2014 Biotech d’Avenir, a prize awarded to one of the fastest-growing, most innovative & dynamic biotech company of the year - Theravectys.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

In addition, THERAVECTYS is proud to announce the launch of its responsive and easy-to-navigate website theravectys.com featuring new sections & content.

A special prize granted by Deloitte Technology Fast 50
Over the last 13 years, this annual event has gathered French leading actors to recognize the fastest-growing companies and the most successful fundraisers of the year.
For the first time since its creation, Deloitte Technology Fast 50 showcased Biotech & Medtech and granted THERAVECTYS with the “Biotech d’Avenir” award in recognition of its continuous efforts to develop innovative therapeutic vaccines and immunotherapies in cancer and infectious diseases.
“We are convinced that all rewarded companies are spear-heading tomorrow’s economic activity and are the catalysts of a dynamic growth leading to jobs and value," said Ariane Bucaille and Vincent Gros, both Partners of Deloitte Technology Fast 50.

A new, trendy & highly-functional website
THERAVECTYS enjoys an entirely new website inspired by the company’s logo and graphic chart featuring current design trends. With its light-colored background, large pictures for a maximum graph-effect and animated colored icons, the website offers a pleasant and easy way to navigate.
Seven sections are reachable from the header menu and are supplemented by linked information reachable through the footer, including links to the main social networks. The highly-functional design allows an easy access to company’s Vision and Mission as well as a detailed review of its technology platform, ongoing programs and agenda.
Discover THERAVECTYS cutting-edge technology in “Our Science” and navigate through the many sections such as “Technology” where you will learn everything about lentiviral vectors and their mode of action,“Manufacturing” will take you through the process development of new vaccine candidates for clinical trials. Other Chapters such as “Our Pipeline” and “Clinical Trials” will provide you with a detailed overview of the company’s R&D activities and pipeline across a variety of indications as well as regular updates on ongoing clinical trials.

About Theravectys

THERAVECTYS (theravectys.com) is privately-owned, fully-integrated discovery and clinical development biotech company originating from the Pasteur Institute.
THERAVECTYS capitalizes over 15 years of fundamental research in the field of lentiviral vectors and has secured worldwide exclusive rights to Pasteur Institute intellectual property.
Based on its lentiviral vector technology platform, THERAVECTYS develops therapeutic vaccines and immunotherapies to fight cancers and infectious diseases, including a proprietary and differentiated CAR T-cell technology platform.
The company is strongly supported by renowned investors and former global biopharmaceutical executives and is rapidly progressing in its R&D activities and in-house GMP production capabilities.
Alone and in collaboration with partners, THERAVECTYS is accelerating its clinical development programs and is planning to initiate two additional phase I/II clinical trials in oncology in 2015.

About Deloitte

“Deloitte” is the brand under which tens of thousands of dedicated professionals in independent firms throughout the world collaborate to provide audit, consulting, financial advisory, risk management, tax and related services to select clients. These firms are members of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”). Each DTTL member firm provides services in particular geographic areas and is subject to the laws and professional regulations of the particular country or countries in which it operates. Each DTTL member firm is structured in accordance with national laws, regulations, customary practice, and other factors, and may secure the provision of professional services in its territory through subsidiaries, affiliates, and other related entities. Not every DTTL member firm provides all services, and certain services may not be available to attest clients under the rules and regulations of public accounting. DTTL and each DTTL member firm are legally separate and independent entities, which cannot obligate each other. DTTL and each DTTL member firm are liable only for their own acts and omissions, and not those of each other. DTTL does not provide services to clients.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Theravectys

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


THERAVECTYS Launches its New Website & Wins Deloitte Technology Fast50 2014 Biotech D’Avenir Award

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Audrey Bonafos - Theravectys.com 
+33(0)1 43 90 14 21 press[.]theravectys.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Theravectys securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Theravectys / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)